Zacks Investment Research cut shares of Chimerix (NASDAQ:CMRX) from a hold rating to a sell rating in a research note released on Tuesday.
According to Zacks, “Chimerix, Inc. engages in the discovery, development and commercialization of oral antiviral therapeutics for various medical needs. The Company is developing various product candidates for the treatment of dsDNA viruses, HIV, hepatitis C, influenza and smallpox which are under different phases of clinical development. It is also screening our proprietary Chimerix Chemical Library for compounds with activity against dengue virus, malaria and tuberculosis. Chimerix, Inc. is headquartered in Durham, North Carolina. “
Separately, ValuEngine raised Chimerix from a strong sell rating to a sell rating in a report on Wednesday, October 11th.
Chimerix (NASDAQ:CMRX) last announced its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.43) by $0.06. The firm had revenue of $0.90 million during the quarter, compared to the consensus estimate of $0.81 million. Chimerix had a negative return on equity of 26.00% and a negative net margin of 1,440.67%. equities analysts forecast that Chimerix will post -1.6 EPS for the current fiscal year.
In other Chimerix news, insider Linda M. Richardson sold 19,833 shares of the business’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $4.47, for a total value of $88,653.51. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 4.40% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of CMRX. Rhumbline Advisers lifted its stake in Chimerix by 7.3% in the second quarter. Rhumbline Advisers now owns 48,541 shares of the biopharmaceutical company’s stock valued at $265,000 after buying an additional 3,300 shares during the last quarter. State of Wisconsin Investment Board purchased a new stake in Chimerix in the second quarter valued at approximately $185,000. Bank of New York Mellon Corp lifted its stake in Chimerix by 3.4% in the second quarter. Bank of New York Mellon Corp now owns 253,367 shares of the biopharmaceutical company’s stock valued at $1,381,000 after buying an additional 8,287 shares during the last quarter. Victory Capital Management Inc. lifted its stake in Chimerix by 88.7% in the second quarter. Victory Capital Management Inc. now owns 229,544 shares of the biopharmaceutical company’s stock valued at $1,251,000 after buying an additional 107,900 shares during the last quarter. Finally, AXA lifted its stake in Chimerix by 284.9% in the second quarter. AXA now owns 258,573 shares of the biopharmaceutical company’s stock valued at $1,409,000 after buying an additional 191,400 shares during the last quarter. Institutional investors own 70.32% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece of content was posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.com-unik.info/2018/01/12/zacks-investment-research-downgrades-chimerix-cmrx-to-sell.html.
Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.